Biomarin Pharmaceutical Inc (BMRN)

BMRN (NASDAQ:Drugs)
$91.83
pos +4.62
+5.30%
Today's Range: 88.12 - 91.85 | BMRN Avg Daily Volume: 1,187,600
Last Update: 12/18/14 - 4:00 PM EST
Volume: 1,416,510
YTD Performance: 23.97%
Open: $89.00
Previous Close: $87.21
52 Week Range: $55.04 - $96.36
Oustanding Shares: 147,465,546
Market Cap: 12,690,884,889
6-Month Chart
TheStreet Ratings Grade for BMRN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 11 10
Moderate Buy 1 1 0 0
Hold 4 4 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.56 1.56 1.63 1.67
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -97.80
Price Earnings Comparisons:
BMRN Sector Avg. S&P 500
-97.80 0.00 24.82
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
27.86% 28.08% 176.24%
GROWTH 12 Mo 3 Yr CAGR
Revenue 9.50 0.46 0.13
Net Income 0.00 -1.86 0.00
EPS 0.00 -1.64 0.00
Earnings for BMRN:
EBITDA -0.10B
Revenue 0.55B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $-0.61 $-0.65 $-1.06 $-2.12
Number of Analysts 9 4 11 11
High Estimate $-0.52 $-0.58 $-0.96 $-0.73
Low Estimate $-0.68 $-0.82 $-1.12 $-2.93
Prior Year $-0.27 $-0.27 $-0.76 $-1.06
Growth Rate (Year over Year) -124.69% -140.74% -39.35% -100.43%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Dec 15, 2014 | 7:08 AM EST

Reams of stocks make sense on a pullback. And what looks bad? Anything even remotely connected to oil and gas.

By

Jim Cramer

 | Dec 2, 2014 | 6:06 PM EST

Stocks, like sports, are unfair sometimes. This is one of those times.

By

Jim Cramer

 | Dec 1, 2014 | 9:16 AM EST

As 2014 winds down, you could almost throw darts at these standout groups -- but here are my own picks.

bullishBioMarin Pharma price target raised at Jefferies

Nov 25, 2014 | 7:40 AM EST

BMRN price target raised to $100 from $87, said Jefferies. Favorable view following acquisition of Prosensa. Buy rating remains.

bullishBiomarin upgraded at Wells

Nov 3, 2014 | 7:57 AM EST

BMRN was upgraded from Market Perform to Outperform, Wells Fargo said. Company has multiple potential clinical catalysts in 2015.

By

Robert Moreno

 | Oct 16, 2014 | 1:49 PM EDT

Here are three stock that have returned to former breakout levels.

By

Timothy Collins

 | Sep 29, 2014 | 12:15 PM EDT

Use the oversold bounces for trimming, cutting or hedging positions.

By

Bob Byrne

 | Jul 9, 2014 | 7:30 AM EDT

The focus is on all things momentum.

By

Bob Byrne

 | Jun 23, 2014 | 7:30 AM EDT

For Es, I believe the odds will remain in the bulls' favor.

By

Bob Byrne

 | Jun 19, 2014 | 7:30 AM EDT

No reason to be bearish on the SPY.

My sense is that if yesterday's upmove was not the start of a vertical upside blow-off tha...
Oracle is today's top gainer in the S&P 500 following last night's Q2 earnings r...
If AAPL is going to continue to rally....this cluster zone and prior swing high need to be...
Yesterday and today was the classic case of watching realized vol. in the SPX and other in...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.